This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Ascendis Pharma Direct Lists on Nasdaq
Business direct listing

Ascendis Pharma Direct Lists on Nasdaq

Analysis based on 6 articles · First reported Apr 08, 2026 · Last updated Apr 20, 2026

Sentiment
20
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The direct listing of Ascendis Pharma's ordinary shares on Nasdaq-100 is expected to broaden access for global investors and potentially increase institutional ownership and trading liquidity for Ascendis Pharma shares. This move could lead to a more stable and liquid market for the company's stock.

Biotechnology Pharmaceuticals
Event Summary

Ascendis Pharma announced and subsequently commenced the direct listing of its ordinary shares on Nasdaq-100, effective April 20, 2026. This transition involved the mandatory exchange of all outstanding American Depositary Shares (ADSs) for ordinary shares, with each ADS converting to one ordinary share. Scott T. Smith, CFO of Ascendis Pharma, stated that this simplified listing structure is intended to broaden access to global investment in Ascendis Pharma and may facilitate inclusion in certain equity indexes, potentially enhancing institutional ownership and trading liquidity. Ascendis Pharma, a global biopharmaceutical company headquartered in Denmark with facilities in the United States, aims to make a meaningful difference for patients through its TransCon technology platform.

Entities Involved
stock
Ascendis Pharma
Ascendis Pharma transitioned its listing from American Depositary Shares (ADSs) to ordinary shares directly on Nasdaq-100, aiming to broaden access to global investment and potentially enhance institutional ownership and trading liquidity.
Importance 100.0 Sentiment 20.0
index
Nasdaq-100
Nasdaq-100 is the exchange where Ascendis Pharma's ordinary shares commenced trading, replacing its previous ADS listing.
Importance 80.0 Sentiment 10.0
per
Scott T. Smith
Scott T. Smith, CFO of Ascendis Pharma, commented on the benefits of the direct listing, stating it would broaden access to global investment and potentially facilitate inclusion in equity indexes.
Importance 30.0 Sentiment 10.0
cnt
Denmark
Importance 0.0 Sentiment 0.0
cnt
United States
Importance 0.0 Sentiment 0.0
Relationships
Nasdaq-100 related ↔ United States
Denmark related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.